IVDR work is often underestimated by teams that are familiar with general device regulation but have not yet worked through the evidence and documentation logic specific to IVDs. Intended purpose, classification, performance evaluation, and post-market obligations all have their own real consequences.
Qmed supports IVD manufacturers with IVDR consulting that is grounded in those realities. We help teams make the right decisions earlier, sequence the work properly, and connect evidence, documentation, and regulatory strategy in a way that can support market access.
What this service covers
Support can include IVDR interpretation, classification, intended-purpose review, performance-evaluation planning, analytical and clinical performance questions, technical-documentation support, route-to-market decisions, UDI and registration readiness, and post-market planning relevant to the IVD lifecycle.
That can be delivered as focused advisory support or as part of a broader programme involving clinical evidence strategy, technical documentation, and execution-facing work where additional evidence generation is needed.
Typical situations
Some organisations are moving legacy or evolving portfolios into a stricter framework than they were built for. Others are early enough that good decisions now can still prevent major rework later. In both cases, unclear intended purpose and weak evidence logic tend to surface repeatedly.
Qmed helps make those issues visible earlier and translate them into a workable plan. Where relevant, we can also help teams think through how EU and UK pathways affect sequencing and workload.
Talk to Qmed
Tell us where your IVDR workstream needs specialist support—and whether the pressure is mainly strategic, evidentiary, or documentation-related.